TrialClinical and molecular hepatology2025

HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study.

Vincent Wai-Sun Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.